DHANUKA - Dhanuka Agritech Ltd. Share Price

The management of Dhanuka Agritech Limited provided a positive outlook despite a challenging operating environment for the agrochemical industry. For Q4 FY '25-26, revenue from operations reached Rs.483.34 crores, an increase of approximately 9% compared to Rs.442.02 crores in Q4 FY '24-25. EBITDA rose to Rs.124.89 crores from Rs.109.75 crores year-on-year, and profit after tax improved significantly to Rs.97.77 crores from Rs.75.50 crores in the previous year.

For FY '27, management anticipates low double-digit revenue growth, expecting sales from the Bayer products to contribute around Rs.60 crore. However, they noted that total sales from Bayer products will not be fully realized until FY '28. The expected guidance includes a revenue impact of Rs.40 crore owing to the absence of GST refunds and a slight decline in economic benefits.

Forward-looking points include a proposed buyback of up to Rs.70 crores at a maximum buyback price of Rs.1,400 per equity share, reflecting confidence in the company's cash flow and growth prospects. Additionally, they introduced an Employee Stock Option Plan (ESOP) aimed at enhancing organizational alignment and entrepreneurial spirit.

Management highlighted strategic priorities: strengthening the product portfolio, expanding reach to farmers, and enhancing operational excellence. They also indicated the agricultural sector's fundamentals remain strong in the medium to long term, reinforcing confidence despite short-term challenges. With ongoing investments in product development and an established distribution network servicing 10 million farmers, the company is positioned for sustained growth and value creation.

Q1: Sir, my question is about two products which were acquired by a buyer. Have we launched any new products within those products and also added any new customers?

Answer: Thank you for your question. The two products, Triadimenol and Iprovalicarb from Bayer, are still being commercialized by Bayer in certain markets. We have appointed customers in five countries, with discussions ongoing in ten more. Currently, we haven't launched new products from this portfolio, but we did introduce Melody Duo in India last year.

Q2: In terms of the Q4 Result, was there any element of pre-placement into the market?

Answer: The placement was similar to the previous year; nothing significant has changed. The Q4 sales pattern remained consistent, without notable pre-placements affecting the results.

Q3: Regarding guidance for FY '27, considering Bayer's product consolidation and the previous ban, how do you assess the base business growth?

Answer: For FY '27, we anticipate a low double-digit growth; however, there will be a Rs. 40 crore impact from the GST refund and net economic benefit loss. The Bayer sales won't be fully recognized this year but will start ramping up next year.

Q4: For FY '26, how much Bayer sales have been recorded, and what expectations do you have for FY '27?

Answer: In FY '26, Bayer products contributed approximately Rs. 27 crore. For FY '27, we expect this to more than double to around Rs. 60 crore as we ramp up production and sales of acquired products.

Q5: How are the early trends in terms of acreage for Kharif crops? Do you see soybean acreage increasing given its price rise?

Answer: Cotton acreage is expected to increase significantly this year, while soybean, competing with other crops, may have mixed results. The increase in soybean prices could positively impact our portfolio if it gains ground, particularly with our herbicides.

Q6: Your other expenses have gone down significantly. Can you explain why?

Answer: The reduction in other expenses is due to effective expense management implemented at the end of November, leading to lower operational costs in Q4. Savings from field promotion expenses also contributed significantly to this decline.

Q7: What is the impact of raw material inflation on your pricing strategy?

Answer: Although we are experiencing 5%-7% inflation in raw materials, passing this on to customers will take time. Some part of the price adjustments has already been reflected, but full compensation will develop gradually throughout Q2.

Q8: Could you elaborate on how you are managing inventory differently compared to industry norms?

Answer: Our production strategy focuses on small batch sizes rather than economies of scale, which allows us to adapt quickly to market demands. As a result, we maintain a healthy inventory turnover and manage receivables better than industry standards.

These answers summarize the important inquiries and respective responses from the earnings call Q&A section, reflecting the company's financial situation and its strategies for future growth.